DFMO: Targeted risk reduction therapy for colorectal neoplasia

Best Practice and Research: Clinical Gastroenterology

Volumn 25, Issue 4-5, 2011, Pages 495-506

  Laukaitis, Christina M ^a   Gerner, Eugene W ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Chemoprevention; Colorectal cancer; DFMO; Polyamines

Indexed keywords

ACYLTRANSFERASE; CELECOXIB; EFLORNITHINE; NONSTEROID ANTIINFLAMMATORY AGENT; POLYAMINE; SPERMIDINE; SPERMINE ACETYLTRANSFERASE; SULINDAC; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AFRICAN TRYPANOSOMIASIS; ANEMIA; ARTICLE; ASTHENIA; CANCER RISK; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; CLINICAL TRIAL (TOPIC); COLON ADENOMA; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL TUMOR; DRUG BIOAVAILABILITY; DRUG EFFICACY; DYSPEPSIA; FLATULENCE; GASTROINTESTINAL TOXICITY; GENETIC PREDISPOSITION; HEARING LOSS; HIRSUTISM; HUMAN; NONHUMAN; OTOTOXICITY; RASH; RISK REDUCTION; TINNITUS; VOMITING;

ADENOMA; ANIMALS; ANTICARCINOGENIC AGENTS; CHEMOPREVENTION; COLORECTAL NEOPLASMS; EFLORNITHINE; ENZYME INHIBITORS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; ORNITHINE DECARBOXYLASE; PRECANCEROUS CONDITIONS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 82455192451     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2011.09.007     Document Type: Article

References (101)

1. P. Bey, C. Danzin, and V. Van Dorsselaer Analogues of ornithine as inhibitors of ornithine decarboxylase. New deductions concerning the topography of the enzyme's active site J Med Chem 21 1 1978 50 55
2. F.L. Meyskens Jr., and E.W. Gerner Development of difluoromethylornithine (DFMO) as a chemoprevention agent Clin Cancer Res 5 5 1999 945 951 (Pubitemid 29233206)
3. F.L. Meyskens Jr., C.E. McLaren, and D. Pelot Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial Cancer Prev Res (Phila Pa) 1 1 2008 32 38
4. E.L. White, L.J. Ross, and S.M. Schmid Screening of potential cancer-preventing chemicals for inhibition of induction of ornithine decarboxylase in epithelial cells from rat trachea Oncol Rep 5 3 1998 717 722 (Pubitemid 28189335)
5. J. Shapiro, and H. Lui Vaniqa-eflornithine 13.9% cream Skin Therapy Lett 6 7 2001 1 3 5
6. J.G. Hickman, F. Huber, and M. Palmisano Human dermal safety studies with eflornithine HCl 13.9% cream (Vaniqa), a novel treatment for excessive facial hair Curr Med Res Opin 16 4 2001 235 244 (Pubitemid 32221480)
7. J.E. Wolf Jr., D. Shander, and F. Huber Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair Int J Dermatol 46 1 2007 94 98 (Pubitemid 46029734)
8. S.D. Hursting, T.J. Slaga, and S.M. Fischer Mechanism-based cancer prevention approaches: targets, examples, and the use of transgenic mice J Natl Cancer Inst 91 3 1999 215 225 (Pubitemid 29090990)
9. G.D. Luk, and R.A. Casero Jr. Polyamines in normal and cancer cells Adv Enzyme Regul 26 1987 91 105
10. R.F. Jacoby, C.E. Cole, and K. Tutsch Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos Cancer Res 60 7 2000 1864 1870 (Pubitemid 30207645)
11. C.V. Rao, K. Tokumo, and J. Rigotty Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha- difluoromethylornithine, 16 alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination Cancer Res 51 17 1991 4528 4534
12. S.H. Erdman, N.A. Ignatenko, and M.B. Powell APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse Carcinogenesis 20 9 1999 1709 1713 (Pubitemid 29410548)
13. A.Y. Esmat, F.M. Refaie, and M.H. Shaheen Chemoprevention of prostate carcinogenesis by DFMO and/or finasteride treatment in male Wistar rats Tumori 88 6 2002 513 521 (Pubitemid 36193903)
14. S. Gupta, N. Ahmad, and S.R. Marengo Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice Cancer Res 60 18 2000 5125 5133
15. H.J. Thompson, L.D. Meeker, and E.J. Herbst Effect of concentration of d, l-2-difluoromethylornithine on murine mammary carcinogenesis Cancer Res 45 3 1985 1170 1173 (Pubitemid 15111278)
16. N.A. Ignatenko, H. Zhang, and G.S. Watts The chemopreventive agent alpha-difluoromethylornithine blocks Ki-ras-dependent tumor formation and specific gene expression in Caco-2 cells Mol Carcinog 39 4 2004 221 233 (Pubitemid 38452242)
17. U.M. Wallon, L.R. Shassetz, and A.E. Cress Polyamine-dependent expression of the matrix metalloproteinase matrilysin in a human colon cancer-derived cell line Mol Carcinog 11 3 1994 138 144 (Pubitemid 24372805)
18. L. Alhonen-Hongisto, D.F. Deen, and L.J. Marton Time dependence of the potentiation of 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity caused by alpha-difluoromethylornithine-induced polyamine depletion in 9L rat brain tumor cells Cancer Res 44 5 1984 1819 1822 (Pubitemid 14145720)
19. W. Choi, E.W. Gerner, and L. Ramdas Combination of 5-fluorouracil and N1, N11-diethylnorspermine markedly activates spermidine/spermine N1-acetyltransferase expression, depletes polyamines, and synergistically induces apoptosis in colon carcinoma cells J Biol Chem 280 5 2005 3295 3304 (Pubitemid 40223791)
20. Y. Takahashi, M. Mai, and K. Nishioka alpha-difluoromethylornithine induces apoptosis as well as anti-angiogenesis in the inhibition of tumor growth and metastasis in a human gastric cancer model Int J Cancer 85 2 2000 243 247 (Pubitemid 30023074)
21. M. Takigawa, M. Enomoto, and Y. Nishida Tumor angiogenesis and polyamines: alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits B16 melanoma-induced angiogenesis in ovo and the proliferation of vascular endothelial cells in vitro Cancer Res 50 13 1990 4131 4138 (Pubitemid 20225641)
22. M.E. Tome, S.M. Fiser, and E.W. Gerner Consequences of aberrant ornithine decarboxylase regulation in rat hepatoma cells J Cell Physiol 158 2 1994 237 244 (Pubitemid 24063550)
23. X.S. Wan, Z. Zhou, and A.R. Kennedy In vitro evaluation of chemopreventive agents using cultured human prostate epithelial cells Oncol Rep 10 6 2003 2009 2014
24. S. Zaletok, S.N. Alexandrova, and N. Berdynskykh Role of polyamines in the function of nuclear transcription factor NF-kappaB in breast cancer cells Exp Oncol 26 3 2004 221 225
25. R.R. Love, P.P. Carbone, and A.R. Verma Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine J Natl Cancer Inst 85 9 1993 732 737 (Pubitemid 23133595)
26. V.A. Levin, J.M. Uhm, and K.A. Jaeckle Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme Clin Cancer Res 6 10 2000 3878 3884
27. F.L. Meyskens, E.M. Kingsley, and T. Glattke A phase II study of alpha-difluoromethylornithine (DFMO) for the treatment of metastatic melanoma Invest New Drugs 4 3 1986 257 262 (Pubitemid 17205956)
28. P.P. McCann, and A.E. Pegg Ornithine decarboxylase as an enzyme target for therapy Pharmacol Ther 54 2 1992 195 215
29. V.A. Levin, K. Lamborn, and W. Wara Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children Neuro Oncol 2 1 2000 22 28
30. J. Leveque, F. Burtin, and V. Catros-Quemener The gastrointestinal polyamine source depletion enhances DFMO induced polyamine depletion in MCF-7 human breast cancer cells in vivo Anticancer Res 18 4A 1998 2663 2668 (Pubitemid 28386564)
31. F.L. Meyskens Jr., and E.W. Gerner Development of difluoromethylornithine as a chemoprevention agent for the management of colon cancer J Cell Biochem Suppl 22 1995 126 131
32. D.S. Alberts, R.T. Dorr, and J.G. Einspahr Chemoprevention of human actinic keratoses by topical 2- (difluoromethyl)-dl-ornithine Cancer Epidemiol Biomarkers Prev 9 12 2000 1281 1286 (Pubitemid 32044795)
33. H.H. Bailey, K. Kim, and A.K. Verma A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}- difluoromethylornithine in subjects with previous history of skin cancer Cancer Prev Res (Phila) 3 1 2010 35 47
34. A.R. Simoneau, E.W. Gerner, and R. Nagle The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial Cancer Epidemiol Biomarkers Prev 17 2 2008 292 299 (Pubitemid 351272778)
35. A.T. Vlastos, L.A. West, and E.N. Atkinson Results of a phase II double-blinded randomized clinical trial of difluoromethylornithine for cervical intraepithelial neoplasia grades 2 to 3 Clin Cancer Res 11 1 2005 390 396 (Pubitemid 40075819)
36. E. Messing, K.M. Kim, and F. Sharkey Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer J Urol 176 2 2006 500 504 (Pubitemid 43949406)
37. C.J. Fabian, B.F. Kimler, and D.A. Brady A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers Clin Cancer Res 8 10 2002 3105 3117 (Pubitemid 35155020)
38. F.A. Sinicrope, R. Broaddus, and N. Joshi Evaluation of difluoromethylornithine for the chemoprevention of Barrett's esophagus and mucosal dysplasia Cancer Prev Res (Phila) 4 6 2011 829 839
39. J.O. Boyle, F.L. Meyskens Jr., and H.S. Garewal Polyamine contents in rectal and buccal mucosae in humans treated with oral difluoromethylornithine Cancer Epidemiol Biomarkers Prev 1 2 1992 131 135
40. F.L. Meyskens Jr., E.W. Gerner, and S. Emerson Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention J Natl Cancer Inst 90 16 1998 1212 1218 (Pubitemid 28407087)
41. F.L. Meyskens Jr., S.S. Emerson, and D. Pelot Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps J Natl Cancer Inst 86 15 1994 1122 1130 (Pubitemid 24249297)
42. G. Andersson, and O. Heby Polyamine and nucleic acid concentrations in Ehrlich ascites carcinoma cells and liver of tumor-bearing mice at various stages of tumor growth J Natl Cancer Inst 48 1 1972 165 172
43. D.H. Russell, and C.C. Levy Polyamine accumulation and biosynthesis in a mouse L1210 leukemia Cancer Res 31 3 1971 248 251
44. U.K. Basuroy, and E.W. Gerner Emerging concepts in targeting the polyamine metabolic pathway in epithelial cancer chemoprevention and chemotherapy J Biochem 139 1 2006 27 33 (Pubitemid 43258843)
45. M.E. Martinez, T.G. O'Brien, and K.E. Fultz Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene Proc Natl Acad Sci USA 100 13 2003 7859 7864 (Pubitemid 36760060)
46. N. Babbar, N.A. Ignatenko, and R.A. Casero Jr. Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer J Biol Chem 278 48 2003 47762 47775 (Pubitemid 37523223)
47. N. Babbar, E.W. Gerner, and R.A. Casero Jr. Induction of spermidine/spermine N1-acetyltransferase (SSAT) by aspirin in Caco-2 colon cancer cells Biochem J 394 Pt 1 2006 317 324 (Pubitemid 43259681)
48. N.A. Ignatenko, D.G. Besselsen, and U.K. Roy Dietary putrescine reduces the intestinal anticarcinogenic activity of sulindac in a murine model of familial adenomatous polyposis Nutr Cancer 56 2 2006 172 181 (Pubitemid 46417677)
49. N.A. Ignatenko, D.G. Besselsen, and D.E. Stringer Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis Nutr Cancer 60 Suppl. 1 2008 30 35
50. N. Babbar, and E.W. Gerner Polyamines as modifiers of genetic risk factors in human intestinal cancers Biochem Soc Trans 31 2 2003 388 392 (Pubitemid 36520683)
51. E.W. Gerner, and F.L. Meyskens Jr. Polyamines and cancer: old molecules, new understanding Nat Rev Cancer 4 10 2004 781 792 (Pubitemid 39331150)
52. F.M. Giardiello, S.R. Hamilton, and L.M. Hylind Ornithine decarboxylase and polyamines in familial adenomatous polyposis Cancer Res 57 2 1997 199 201 (Pubitemid 27036592)
53. M. Linsalata, M. Notarnicola, and M.G. Caruso Polyamine biosynthesis in relation to K-ras and p-53 mutations in colorectal carcinoma Scand J Gastroenterol 39 5 2004 470 477 (Pubitemid 38626628)
54. H.M. Wallace, and R. Caslake Polyamines and colon cancer Eur J Gastroenterol Hepatol 13 9 2001 1033 1039 (Pubitemid 32905194)
55. N. Seiler, C.L. Atanassov, and F. Raul Polyamine metabolism as target for cancer chemoprevention (review) Int J Oncol 13 5 1998 993 1006 (Pubitemid 28506070)
56. E.W. Gerner, H.S. Garewal, and S.S. Emerson Gastrointestinal tissue polyamine contents of patients with Barrett's esophagus treated with alpha-difluoromethylornithine Cancer Epidemiol Biomarkers Prev 3 4 1994 325 330 (Pubitemid 24181577)
57. L.J. Hixson, S.S. Emerson, and L.R. Shassetz Sources of variability in estimating ornithine decarboxylase activity and polyamine contents in human colorectal mucosa Cancer Epidemiol Biomarkers Prev 3 4 1994 317 323 (Pubitemid 24181576)
58. M. Auvinen, A. Paasinen, and L.C. Andersson Ornithine decarboxylase activity is critical for cell transformation Nature 360 6402 1992 355 358 (Pubitemid 23000675)
59. A. Tabib, and U. Bachrach Role of polyamines in mediating malignant transformation and oncogene expression Int J Biochem Cell Biol 31 11 1999 1289 1295 (Pubitemid 29486710)
60. L.J. Hixson, H.S. Garewal, and D.L. McGee Ornithine decarboxylase and polyamines in colorectal neoplasia and mucosa Cancer Epidemiol Biomarkers Prev 2 4 1993 369 374
61. Y. Elitsur, J.A. Moshier, and R. Murthy Polyamine levels, ornithine decarboxylase (ODC) activity, and ODC-mRNA expression in normal and cancerous human colonocytes Life Sci 50 19 1992 1417 1424
62. M.F. Mitchell, G. Tortolero-Luna, and J.J. Lee Polyamine measurements in the uterine cervix J Cell Biochem Suppl 28-29 1997 125 132 (Pubitemid 28246636)
63. U. Bachrach Polyamines as markers of malignancy Prog Drug Res 39 1992 9 33
64. A.E. Pegg Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy Cancer Res 48 4 1988 759 774 (Pubitemid 18061860)
65. X. Guo, J.N. Rao, and L. Liu Regulation of adherens junctions and epithelial paracellular permeability: a novel function for polyamines Am J Physiol Cell Physiol 285 5 2003 C1174 C1187
66. C. Danzin, M.J. Jung, and N. Claverie Effects of alpha- difluoromethylornithine, an enzyme-activated irreversible inhibitor or ornithine decarboxylase, on testosterone-induced regeneration of prostate and seminal vesicle in castrated rats Biochem J 180 3 1979 507 513 (Pubitemid 9208283)
67. C. Danzin, M.J. Jung, and J. Grove Effect of alpha- difluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase, on polyamine levels in rat tissues Life Sci 24 6 1979 519 524 (Pubitemid 9123397)
68. S.M. Oredsson, B. Nicander, and O. Heby Implications for a reduced DNA-elongation rate in polyamine-depleted cells Eur J Biochem 190 3 1990 483 489
69. C. Bello-Fernandez, G. Packham, and J.L. Cleveland The ornithine decarboxylase gene is a transcriptional target of c-Myc Proc Natl Acad Sci USA 90 16 1993 7804 7808 (Pubitemid 23250039)
70. A. Pena, C.D. Reddy, and S. Wu Regulation of human ornithine decarboxylase expression by the c-Myc.Max protein complex J Biol Chem 268 36 1993 27277 27285 (Pubitemid 24006447)
71. P. Celano, S.B. Baylin, and F.M. Giardiello Effect of polyamine depletion on c-myc expression in human colon carcinoma cells J Biol Chem 263 12 1988 5491 5494
72. P.P. Carbone, J.A. Douglas, and J. Thomas Bioavailability study of oral liquid and tablet forms of alpha-difluoromethylornithine Clin Cancer Res 6 10 2000 3850 3854
73. H.M. Wallace, and A.V. Fraser Inhibitors of polyamine metabolism: review article Amino Acids 26 4 2004 353 365 (Pubitemid 39093138)
74. H.M. Wallace, A.V. Fraser, and A. Hughes A perspective of polyamine metabolism Biochem J 376 Pt 1 2003 1 14 (Pubitemid 37487199)
75. P.M. Harari, D.J. Fuller, and S.W. Carper Polyamine biosynthesis inhibitors combined with systemic hyperthermia in cancer therapy Int J Radiat Oncol Biol Phys 19 1 1990 89 96 (Pubitemid 20239790)
76. G.A. Piazza, D.S. Alberts, and L.J. Hixson Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels Cancer Res 57 14 1997 2909 2915 (Pubitemid 27315038)
77. G.A. Piazza, A.K. Rahm, and T.S. Finn Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction Cancer Res 57 12 1997 2452 2459 (Pubitemid 27255906)
78. G. Steinbach, P.M. Lynch, and R.K. Phillips The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis N Engl J Med 342 26 2000 1946 1952 (Pubitemid 30419089)
79. G.N. Levy Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer Faseb J 11 4 1997 234 247 (Pubitemid 27118324)
80. K. Niiranen, M. Pietila, and T.J. Pirttila Targeted disruption of spermidine/spermine N1-acetyltransferase gene in mouse embryonic stem cells. Effects on polyamine homeostasis and sensitivity to polyamine analogues J Biol Chem 277 28 2002 25323 25328 (Pubitemid 34951842)
81. M. Belting, L. Borsig, and M.M. Fuster Tumor attenuation by combined heparan sulfate and polyamine depletion Proc Natl Acad Sci USA 99 1 2002 371 376 (Pubitemid 34061935)
82. B.M. Cracchiolo, D.S. Heller, and P.M. Clement Eukaryotic initiation factor 5A-1 (eIF5A-1) as a diagnostic marker for aberrant proliferation in intraepithelial neoplasia of the vulva Gynecol Oncol 94 1 2004 217 222 (Pubitemid 38950524)
83. R.R. Love, R. Jacoby, and M.A. Newton A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer Cancer Epidemiol Biomarkers Prev 7 11 1998 989 992 (Pubitemid 28514098)
84. F.L. Meyskens Jr., E. Surwit, and T.E. Moon Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial J Natl Cancer Inst 86 7 1994 539 543
85. E. Giovannucci Modifiable risk factors for colon cancer Gastroenterol Clin North Am 31 4 2002 925 943 (Pubitemid 35403506)
86. E. Giovannucci Obesity, gender, and colon cancer Gut 51 2 2002 147 (Pubitemid 34791434)
87. E.T. Jacobs, P.A. Thompson, and M.E. Martinez Diet, gender, and colorectal neoplasia J Clin Gastroenterol 41 8 2007 731 746 (Pubitemid 47267759)
88. E. Flossmann, and P.M. Rothwell Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies Lancet 369 9573 2007 1603 1613 (Pubitemid 46710123)
89. T. Muto, H.J. Bussey, and B.C. Morson The evolution of cancer of the colon and rectum Cancer 36 6 1975 2251 2270
90. P.J. Creaven, L. Pendyala, and N.J. Petrelli Evaluation of alpha-difluoromethylornithine as a potential chemopreventive agent: tolerance to daily oral administration in humans Cancer Epidemiol Biomarkers Prev 2 3 1993 243 247
91. M.K. Croghan, M.G. Aickin, and F.L. Meyskens Dose-related alpha-difluoromethylornithine ototoxicity Am J Clin Oncol 14 4 1991 331 335
92. C. Jansen, D.E. Mattox, and K.D. Miller An animal model of hearing loss from alpha-difluoromethylornithine Arch Otolaryngol Head Neck Surg 115 10 1989 1234 1237 (Pubitemid 19257396)
93. C.L. Loprinzi, E.M. Messing, and J.R. O'Fallon Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials Cancer Epidemiol Biomarkers Prev 5 5 1996 371 374 (Pubitemid 26139120)
94. T.R. Pasic, D. Heisey, and R.R. Love alpha-difluoromethylornithine ototoxicity. Chemoprevention clinical trial results Arch Otolaryngol Head Neck Surg 123 12 1997 1281 1286 (Pubitemid 28007375)
95. C.E. McLaren, S. Fujikawa-Brooks, and W.P. Chen Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas Cancer Prev Res (Phila) 1 7 2008 514 521
96. J.A. Zell, A. Ziogas, and N. Ignatenko Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival Clin Cancer Res 15 19 2009 6208 6216
97. J.A. Zell, D. Pelot, and W.P. Chen Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas Cancer Prev Res (Phila Pa) 2 3 2009 209 212
98. S.D. Solomon, J. Wittes, and P.V. Finn Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis Circulation 117 16 2008 2104 2113 (Pubitemid 351572169)
99. J.A. Zell, C.E. McLaren, and W.P. Chen Ornithine Decarboxylase-1 polymorphism, chemoprevention with Eflornithine and sulindac, and outcomes among colorectal adenoma patients J Natl Cancer Inst 2010 [epub ahead of print]
100. S.M. Lippman The dilemma and promise of cancer chemoprevention Nat Clin Pract Oncol 3 10 2006 523 (Pubitemid 44781718)
101. B.M. Psaty, and J.D. Potter Risks and benefits of celecoxib to prevent recurrent adenomas N Engl J Med 355 9 2006 950 952 (Pubitemid 44315987)